ClinicalTrials.gg
CompletedNCT02064816RELIEFUpdated Sep 20, 2018Results posted

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

A Phase 4 interventional study of Rebif® and Rebif® in Multiple Sclerosis, Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-09-20.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
8th of 21
200 · median 80
Started
2014
the only one that year
Phase 4
13 of 21
none open now
Registered
17th of 21
by date
Lead sponsor
5 of 21
Merck KGaA, Darmstadt, Germany

Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 8th largest by enrollment, is the only one that started in 2014, is one of 13 in phase 4, and was the 17th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS) as compared to the evening administration, in subjects with relapsing multiple sclerosis (RMS).

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Multiple Sclerosis, Relapsing-Remitting
  • Interferon beta 1a
  • Rebif®
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 18 and 60 years of age
  • Female subjects must be neither pregnant nor breast-feeding and must lack . Furthermore, female subjects must not have been pregnant from at least three months prior to enter in the study
  • Subjects have RMS according to the revised McDonald Criteria (2010)
  • Subjects with an expanded disability status scale (EDSS) score of less than 6.0
  • Subjects naive to treatment and eligible for treatment with Rebif® 44 three times a week, or patients having received glatiramer acetate with a from at least one month, or patients having received treatment with natalizumab or fingolimod with a wash-out from at least three months
  • Subjects able to self-inject treatment using RebiSmart®
  • Subjects willing and able to comply with the protocol for the duration of the study
  • Subjects have given written to take part in the study

Exclusion criteria

Exclusion Criteria:

  • Subjects have any disease other than MS that could better explain his/her signs and symptoms
  • Subjects who have received any agents within 3 months prior to Baseline
  • Subjects who have received any within 30 days prior to Baseline
  • Subjects have a MS relapse within 30 days prior to Baseline
  • Subjects have inadequate liver function and bone marrow reserve as defined in the protocol
  • Subjects have moderate to severe renal impairment
  • Subjects have any visual or physical impairment that precludes the subjects from self-injecting the treatment using RebiSmart®
  • Subjects have to natural or recombinant interferon, or to any of its
  • Subjects have any to treatment with interferon (IFN) beta 1a according to Summary of Product Characteristics (SmPC)
  • Subjects have any contra-indications to treatment with ibuprofen/paracetamol according to SmPC
  • Obese subjects, defined by greater than 30 kilogram per square meter (kg/m\^2)
  • Subjects have participated in any other trial within 30 days from Baseline
  • Subjects have any other significant disease that in the Investigator's opinion would exclude the subject from the trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Rebif® Morning Administration

    Drug: Rebif®

  • Experimental
    Rebif® Evening Administration

    Drug: Rebif®

Interventions

  • Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.

  • Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 12

    The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 12 is presented in statistical analysis section.

    Time frame: Week 12

Secondary outcomes

  1. Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4 and 8

    The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 4 and 8 is presented in statistical analysis section.

    Time frame: Week 4 and 8

  2. Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Subscale Scores Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4, 8 and 12

    MSTCQ was used as a tool to measure treatment satisfaction, focusing on attributes specific to MS medications. Following sub-scales were assessed: Injection site reactions (ISRs), Global side-effects, Benefits, Pain, Visual Analog Scale (VAS), and Rating of Pain. ISR subscale was defined as sum of scores for questions 17 to 20, with a minimum possible total score of 4 and a maximum possible total score of 20. Global side-effects subscale was defined as sum of scores for questions 21 to 23 with minimum possible total score of 3 and a maximum possible total score of 15. Benefits (question 35); description of pain (question 36); VAS (question 37); rating of pain (question 38) subscales ranged from minimum possible score of 1 and a maximum possible total score of 5. For each of the subscales, lower scores indicated better satisfaction. Difference between both the groups at Week 4, 8 and 12 for individual sub-scales is presented in statistical analysis section.

    Time frame: Week 4, 8 and 12

  3. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 4, 8 and 12

    HADS was used to measure depression and anxiety in subjects. The scale was limited to 14 questions. Seven of the items related to anxiety and 7 related to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.

    Time frame: Baseline, Week 4, 8 and 12

  4. Change From Baseline in Fatigue Severity Scale (FSS) Score at Week 4, 8 and 12

    FSS is a method designed to assess disabling fatigue in all the individuals. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each item assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.

    Time frame: Baseline, Week 4, 8 and 12

  5. Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 4, 8 and 12

    PSQI is a self-rated questionnaire which assess sleep quality and disturbances over a 1-month interval using seven clinically derived components of sleep difficulties: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. PSQI is a summary of 7 components. Each component is scored from 0 to 3, therefore PSQI has a range of 0 (better) to 21 (worse). Interpretation of the PSQI is that a score less than 5 is associated with good sleep quality and a score of 5 or greater is associated with poor sleep quality.

    Time frame: Baseline, Week 4, 8 and 12

  6. Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQOL) Score at Week 4, 8 and 12

    The MusiQoL is a validated 31-item questionnaire describing 9 dimensions: activities of daily living (8 items); psychological well-being (4 items); symptoms (3 items); relationships with friends (4 items); relationships with family (3 items); relationship with healthcare system (3 items); sentimental and sexual life (2 items); coping (2 items); and rejection (2 items). Each of the questions was answered using a 6-point Likert scale ranging from 1 (never/not at all) to 6 (always/very much). The scores of each dimension were obtained by computing mean of the item scores of dimension with negatively worded item scores reversed so that higher scores indicated higher health-related quality of life (QoL). All 9 dimension scores were linearly transformed to a 0 to 100 scale and the average of the 9 dimensions was used to give a Global Score ranging from 0 to 100, where higher scores indicated higher health-related quality of life (QoL).

    Time frame: Baseline, Week 4, 8 and 12

  7. Percentage of Subjects With Treatment Adherence at Week 4, 8 and 12

    Adherence to treatment was calculated as 100 x the number of completed injections the subject administered divided by the expected number of injections. Treatment adherence was divided in two categories: percentage of subjects with less than (\<) 80 percent adherence and percentage of subjects with more than or equal to (\>=) 80 percent adherence.

    Time frame: Week 4, 8 and 12

  8. Change From Baseline in Circulating Levels of Cytokines at Week 12

    Results are presented for three cytokines: leptin, resistin and adiponectin.

    Time frame: Baseline and Week 12

  9. Correlation Between Change From Baseline in Circulating Levels of Cytokines (Leptin, Resistin and Adiponectin) and in Flu Like Symptom (FLS) Score at Week 12

    Correlation was assessed by using Pearson correlation coefficient. The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to MS medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction.

    Time frame: Baseline and Week 12

  10. Correlation Between Change From Baseline in Circulating Levels of Cytokines and in Other MSTCQ Items, HADS, FSS, PSQI and MusiQOL Scores at Week 12

    Correlation was assessed by using Pearson correlation coefficient. MSTCQ, HADS, FSS, PSQI and MusiQOL are described in the above endpoints. Following abbreviations used in the categories: Global side-effects (GLOBSE); description of pain (PAINDESCR).

    Time frame: Baseline and Week 12

  11. Change From Baseline in Cytokines (Leptin and Resistin) Levels at Week 12

    Results are presented for cytokines: leptin and resistin.

    Time frame: Baseline and Week 12

  12. Change From Baseline in Cytokine (Adiponectin) Level at Week 12

    Time frame: Baseline and Week 12

  13. Change From Baseline in Hormone-Like Cytokine (Interleukin-6, 10 and 12) Levels at Week 12

    Time frame: Baseline and Week 12

  14. Change From Baseline in Total Sleep Time (TST) and Rapid Eye Movement (REM) Sleep Time at Week 12

    Polysomnography (PSG) was performed for subjects who participated in the sub study. PSG is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.

    Time frame: Baseline and Week 12

  15. Correlation Between Change From Baseline in Cytokines (Leptin, Resistin and Adiponectin) and Hormone-like Cytokine Levels (Interleukin-6, 10 and 12), and TST and REM Sleep Time at Week 12

    Correlations between change from baseline at Week 12 in TST or REM sleep and the area under the curve (AUC) calculated using the trapezoidal method for cytokine levels (i.e., leptin, resistin, adiponectin, Interleukin (IL)-12, IL 10, and IL 6) were analyzed using Pearson's correlation coefficient. Polysomnography (PSG) was performed for subjects who participated in the sub study.

    Time frame: Baseline and Week 12

  16. Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation

    An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug.

    Time frame: Baseline up to Week 12

07

Results

Posted Sep 20, 2018

Participant flow

The study was conducted at 29 clinical trial sites in Italy.

Participant flow — Overall Study
MilestoneRebif Morning AdministrationRebif Evening Administration
Started10496
Completed9688
Not completed88
Withdrew: Adverse event32
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up21
Withdrew: Therapeutic failure01
Withdrew: Other13

Outcome measures

PrimaryDifference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 12

The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 12 is presented in statistical analysis section.

Time frame:
Week 12
Reported as:
Mean · units on scale
Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 12
units on scaleRebif Morning AdministrationRebif Evening Administration
Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 1212.3 ± 3.8711.8 ± 3.02
Statistical analysis
  • Rebif Morning Administration vs Rebif Evening Administration · Mann-Whitney Non Parametric test · p = 0.277763 · Mean difference (final values): 0.6 · 95% CI -0.46 to 1.56
SecondaryDifference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4 and 8

The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 4 and 8 is presented in statistical analysis section.

Time frame:
Week 4 and 8
Reported as:
Least squares mean · units on scale
Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4 and 8
units on scaleRebif Morning AdministrationRebif Evening Administration
Week 412.4368 (11.7402 to 13.1333)11.0876 (10.3705 to 11.8046)
Week 813.0039 (12.3244 to 13.6834)11.6672 (10.9565 to 12.3779)
Statistical analysis
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.0083 · Least square (ls) mean difference: 1.3492 · 95% CI 0.3495 to 2.3489
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.0079 · Ls mean difference: 1.3367 · 95% CI 0.3534 to 2.3200
SecondaryDifference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Subscale Scores Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4, 8 and 12

MSTCQ was used as a tool to measure treatment satisfaction, focusing on attributes specific to MS medications. Following sub-scales were assessed: Injection site reactions (ISRs), Global side-effects, Benefits, Pain, Visual Analog Scale (VAS), and Rating of Pain. ISR subscale was defined as sum of scores for questions 17 to 20, with a minimum possible total score of 4 and a maximum possible total score of 20. Global side-effects subscale was defined as sum of scores for questions 21 to 23 with minimum possible total score of 3 and a maximum possible total score of 15. Benefits (question 35); description of pain (question 36); VAS (question 37); rating of pain (question 38) subscales ranged from minimum possible score of 1 and a maximum possible total score of 5. For each of the subscales, lower scores indicated better satisfaction. Difference between both the groups at Week 4, 8 and 12 for individual sub-scales is presented in statistical analysis section.

Time frame:
Week 4, 8 and 12
Reported as:
Least squares mean · units on scale
Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Subscale Scores Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4, 8 and 12
units on scaleRebif Morning AdministrationRebif Evening Administration
ISRs subscale Week 410.8459 (10.1609 to 11.5309)10.4456 (9.7177 to 11.1735)
ISRs subscale Week 811.5363 (10.8625 to 12.2101)11.4515 (10.7540 to 12.1490)
ISRs subscale Week 1211.6380 (10.9720 to 12.3041)11.9625 (11.2598 to 12.6652)
Global side-effect subscale: Week 410.2144 (9.6771 to 10.7518)10.2852 (9.7276 to 10.8429)
Global side-effect subscale: Week 810.4111 (9.8698 to 10.9525)10.2214 (9.6567 to 10.7862)
Global side-effect subscale: Week 1210.5879 (10.0456 to 11.1302)10.1782 (9.6132 to 10.7432)
Benefits: Week 43.1325 (2.7856 to 3.4794)3.5408 (3.1912 to 3.8905)
Benefits: Week 83.5779 (3.2207 to 3.9351)3.7137 (3.3622 to 4.0652)
Benefits: Week 123.6059 (3.2467 to 3.9652)3.6640 (3.3062 to 4.0218)
Description of pain: Week 44.3755 (3.2024 to 5.5485)3.7846 (2.5846 to 4.9847)
Description of pain: Week 85.3132 (4.1262 to 6.5003)6.0821 (4.8767 to 7.2875)
Description of pain: Week 125.7853 (4.6089 to 6.9617)5.6431 (4.4239 to 6.8624)
VAS: Week 411.8837 (7.6691 to 16.0983)11.2293 (6.8280 to 15.6305)
VAS: Week 817.2316 (12.9597 to 21.5035)19.4610 (15.0359 to 23.8860)
VAS: Week 1216.1757 (11.9054 to 20.4460)21.5953 (17.1359 to 26.0547)
Rating of pain: Week 41.3073 (1.1008 to 1.5138)1.3004 (1.0846 to 1.5162)
Rating of pain: Week 81.5653 (1.3553 to 1.7753)1.6522 (1.4356 to 1.8688)
Rating of pain: Week 121.4994 (1.2895 to 1.7094)1.7218 (1.5029 to 1.9407)
Statistical analysis
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.4311 · Ls mean difference: 0.4003 · 95% CI -0.5992 to 1.3998
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.8635 · Ls mean difference: 0.08479 · 95% CI -0.8850 to 1.0546
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.5099 · Ls mean difference: -0.3245 · 95% CI -1.2927 to 0.6437
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.8574 · Ls mean difference: -0.07079 · 95% CI -0.8452 to 0.7036
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.6338 · Ls mean difference: 0.1897 · 95% CI -0.5926 to 0.9720
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.3042 · Ls mean difference: 0.4097 · 95% CI -0.3734 to 1.1929
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.1038 · Ls mean difference: -0.4083 · 95% CI -0.9008 to 0.08419
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.5940 · Ls mean difference: -0.1358 · 95% CI -0.6370 to 0.3653
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.8217 · Ls mean difference: -0.05809 · 95% CI -0.5651 to 0.4489
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.4890 · Ls mean difference: 0.5909 · 95% CI -1.0873 to 2.2690
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.3719 · Ls mean difference: -0.7689 · 95% CI -2.4607 to 0.9229
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.8690 · Ls mean difference: 0.1422 · 95% CI -1.5521 to 1.8364
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.8328 · Ls mean difference: 0.6544 · 95% CI -5.4393 to 6.7482
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.4764 · Ls mean difference: -2.2294 · 95% CI -8.3800 to 3.9212
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.0852 · Ls mean difference: -5.4196 · 95% CI -11.5939 to 0.7547
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.9639 · Ls mean difference: 0.006873 · 95% CI -0.2918 to 0.3055
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.5715 · Ls mean difference: -0.08689 · 95% CI -0.3886 to 0.2148
  • Rebif Morning Administration vs Rebif Evening Administration · linear mixed model for repeated measures · p = 0.1502 · Ls mean difference: -0.2224 · 95% CI -0.5256 to 0.08090
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 4, 8 and 12

HADS was used to measure depression and anxiety in subjects. The scale was limited to 14 questions. Seven of the items related to anxiety and 7 related to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.

Time frame:
Baseline, Week 4, 8 and 12
Reported as:
Least squares mean · units on scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 4, 8 and 12
units on scaleRebif Morning AdministrationRebif Evening Administration
Anxiety score: Change at Week 4-0.6625 (-1.1976 to -0.1273)-0.4604 (-1.0106 to 0.08968)
Anxiety score: Change at Week 8-0.7222 (-1.2688 to -0.1755)-0.3763 (-0.9308 to 0.1782)
Anxiety score: Change at Week 12-0.6435 (-1.1879 to -0.09918)0.05023 (-0.5081 to 0.6085)
Depression score: Change at Week 4-0.1539 (-0.8083 to 0.5005)0.2211 (-0.4617 to 0.9038)
Depression score: Change at Week 8-0.2397 (-0.9062 to 0.4267)0.1999 (-0.4835 to 0.8833)
Depression score: Change at Week 120.1906 (-0.4778 to 0.8590)0.1162 (-0.5741 to 0.8066)
SecondaryChange From Baseline in Fatigue Severity Scale (FSS) Score at Week 4, 8 and 12

FSS is a method designed to assess disabling fatigue in all the individuals. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each item assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.

Time frame:
Baseline, Week 4, 8 and 12
Reported as:
Least squares mean · units on scale
Change From Baseline in Fatigue Severity Scale (FSS) Score at Week 4, 8 and 12
units on scaleRebif Morning AdministrationRebif Evening Administration
Change at Week 40.2089 (-0.05810 to 0.4759)0.06901 (-0.2010 to 0.3391)
Change at Week 80.2062 (-0.06211 to 0.4746)0.1366 (-0.1354 to 0.4085)
Change at Week 120.1464 (-0.1253 to 0.4182)0.1942 (-0.08036 to 0.4688)
SecondaryChange From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 4, 8 and 12

PSQI is a self-rated questionnaire which assess sleep quality and disturbances over a 1-month interval using seven clinically derived components of sleep difficulties: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. PSQI is a summary of 7 components. Each component is scored from 0 to 3, therefore PSQI has a range of 0 (better) to 21 (worse). Interpretation of the PSQI is that a score less than 5 is associated with good sleep quality and a score of 5 or greater is associated with poor sleep quality.

Time frame:
Baseline, Week 4, 8 and 12
Reported as:
Least squares mean · units on scale
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 4, 8 and 12
units on scaleRebif Morning AdministrationRebif Evening Administration
Change at Week 4-0.08889 (-0.7690 to 0.5912)0.5747 (-0.1653 to 1.3147)
Change at Week 8-0.4513 (-1.1161 to 0.2136)0.7092 (-0.01588 to 1.4343)
Change at Week 120.07841 (-0.6265 to 0.7833)0.4293 (-0.3270 to 1.1855)
SecondaryChange From Baseline in Multiple Sclerosis International Quality of Life (MusiQOL) Score at Week 4, 8 and 12

The MusiQoL is a validated 31-item questionnaire describing 9 dimensions: activities of daily living (8 items); psychological well-being (4 items); symptoms (3 items); relationships with friends (4 items); relationships with family (3 items); relationship with healthcare system (3 items); sentimental and sexual life (2 items); coping (2 items); and rejection (2 items). Each of the questions was answered using a 6-point Likert scale ranging from 1 (never/not at all) to 6 (always/very much). The scores of each dimension were obtained by computing mean of the item scores of dimension with negatively worded item scores reversed so that higher scores indicated higher health-related quality of life (QoL). All 9 dimension scores were linearly transformed to a 0 to 100 scale and the average of the 9 dimensions was used to give a Global Score ranging from 0 to 100, where higher scores indicated higher health-related quality of life (QoL).

Time frame:
Baseline, Week 4, 8 and 12
Reported as:
Least squares mean · units on scale
Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQOL) Score at Week 4, 8 and 12
units on scaleRebif Morning AdministrationRebif Evening Administration
Global Score: Change at Week 41.6283 (-0.3761 to 3.6326)0.1174 (-1.9196 to 2.1544)
Global Score: Change at Week 81.1439 (-0.8780 to 3.1658)-2.2945 (-4.3568 to -0.2321)
Global Score: Change at Week 120.9670 (-1.0753 to 3.0094)-1.3948 (-3.4796 to 0.6900)
SecondaryPercentage of Subjects With Treatment Adherence at Week 4, 8 and 12

Adherence to treatment was calculated as 100 x the number of completed injections the subject administered divided by the expected number of injections. Treatment adherence was divided in two categories: percentage of subjects with less than (\<) 80 percent adherence and percentage of subjects with more than or equal to (\>=) 80 percent adherence.

Time frame:
Week 4, 8 and 12
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Treatment Adherence at Week 4, 8 and 12
Percentage of subjectsRebif Morning AdministrationRebif Evening Administration
< 80 percent adherence at Week 43.35.9
>= 80 percent adherence at Week 496.794.1
< 80 percent adherence at Week 82.91.5
>= 80 percent adherence at Week 897.198.5
< 80 percent adherence at Week 124.86.3
>= 80 percent adherence at Week 1295.293.7
SecondaryChange From Baseline in Circulating Levels of Cytokines at Week 12

Results are presented for three cytokines: leptin, resistin and adiponectin.

Time frame:
Baseline and Week 12
Reported as:
Mean · microgram per liter (mcg/L)
Change From Baseline in Circulating Levels of Cytokines at Week 12
microgram per liter (mcg/L)Rebif Morning AdministrationRebif Evening Administration
Leptin: Change at Week 12-2.6 ± 3.42-2.6 ± 3.90
Resistin: Change at Week 12-3.1 ± 3.31-3.0 ± 3.77
Adiponectin: Change at Week 122.8 ± 6.382.8 ± 5.51
SecondaryCorrelation Between Change From Baseline in Circulating Levels of Cytokines (Leptin, Resistin and Adiponectin) and in Flu Like Symptom (FLS) Score at Week 12

Correlation was assessed by using Pearson correlation coefficient. The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to MS medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction.

Time frame:
Baseline and Week 12
Reported as:
Number · Correlation coefficient
Correlation Between Change From Baseline in Circulating Levels of Cytokines (Leptin, Resistin and Adiponectin) and in Flu Like Symptom (FLS) Score at Week 12
Correlation coefficientRebif Morning AdministrationRebif Evening Administration
Leptin and FLS: Change at Week 120.088220.03944
Resistin and FLS: Change at Week 12-0.20200-0.01069
Adiponectin and FLS: Change at Week 120.04616-0.13571
SecondaryCorrelation Between Change From Baseline in Circulating Levels of Cytokines and in Other MSTCQ Items, HADS, FSS, PSQI and MusiQOL Scores at Week 12

Correlation was assessed by using Pearson correlation coefficient. MSTCQ, HADS, FSS, PSQI and MusiQOL are described in the above endpoints. Following abbreviations used in the categories: Global side-effects (GLOBSE); description of pain (PAINDESCR).

Time frame:
Baseline and Week 12
Reported as:
Number · Correlation Coefficient
Correlation Between Change From Baseline in Circulating Levels of Cytokines and in Other MSTCQ Items, HADS, FSS, PSQI and MusiQOL Scores at Week 12
Correlation CoefficientRebif Morning AdministrationRebif Evening Administration
Leptin and MSTCQ-ISR: Week 120.00595-0.10214
Resistin and MSTCQ-ISR: Week 12-0.223800.04855
Adiponectin and MSTCQ-ISR: Week 12-0.13365-0.14865
Leptin and MSTCQ-GLOBSE: Week 120.031210.21425
Resistin and MSTCQ-GLOBSE: Week 120.20285-0.12730
Adiponectin and MSTCQ-GLOBSE: Week 120.00169-0.06398
Leptin and MSTCQ-benefits: Week 120.13023-0.10915
Resistin and MSTCQ-benefits: Week 12-0.13544-0.15636
Adiponectin and MSTCQ-benefits: Week 120.107260.04081
Leptin and MSTCQ-PAINDESCR: Week 120.091180.01165
Resistin and MSTCQ-PAINDESCR: Week 12-0.139180.04150
Adiponectin and MSTCQ-PAINDESCR: Week120.070930.01535
Leptin and MSTCQ-VAS: Week 120.34840-0.01433
Resistin and MSTCQ-VAS: Week 12-0.152310.16220
Adiponectin and MSTCQ-VAS: Week 12-0.078400.02109
Leptin and MSTCQ-pain rating: Week 120.16675-0.14381
Resistin and MSTCQ-pain rating: Week 12-0.235310.12355
Adiponectin and MSTCQ-pain rating: Week12-0.08060-0.08718
Leptin and HADS-anxiety: Week 120.00754-0.06360
Resistin and HADS-anxiety: Week 120.024470.07986
Adiponectin and HADS-anxiety: Week 120.062950.08818
Leptin and HADS-depression: Week 120.05226-0.14953
Resistin and HADS-depression: Week 120.01970-0.04154
Adiponectin and HADS-depression: Week 120.032280.19209
Leptin and FSS: Week 120.042560.14284
Resistin and FSS: Week 12-0.23755-0.10961
Adiponectin and FSS: Week 12-0.003260.03090
Leptin and PSQI: Week 120.008730.00099
Resistin and PSQI: Week 12-0.037650.12085
Adiponectin and PSQI: Week 120.257950.24406
Leptin and MusiQoL- Global: Week 12-0.256500.17917
Resistin and MusiQoL-Global: Week 120.121900.21936
Adiponectin and MusiQoL-Global: Week 120.07152-0.05924
SecondaryChange From Baseline in Cytokines (Leptin and Resistin) Levels at Week 12

Results are presented for cytokines: leptin and resistin.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Nanogram/milliliter (ng/mL)
Change From Baseline in Cytokines (Leptin and Resistin) Levels at Week 12
Nanogram/milliliter (ng/mL)Rebif Morning AdministrationRebif Evening Administration
Leptin: Change at Week 12-2.7826 (-6.1880 to 0.6227)-0.7936 (-4.4371 to 2.8499)
Resistin: Change at Week 12-3.6628 (-5.3424 to -1.9831)-5.8360 (-7.6339 to -4.0381)
SecondaryChange From Baseline in Cytokine (Adiponectin) Level at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · microgram per milliliter (mcg/mL)
Change From Baseline in Cytokine (Adiponectin) Level at Week 12
microgram per milliliter (mcg/mL)Rebif Morning AdministrationRebif Evening Administration
Change From Baseline in Cytokine (Adiponectin) Level at Week 122.7093 (-1.0663 to 6.4848)4.3574 (0.3174 to 8.3975)
SecondaryChange From Baseline in Hormone-Like Cytokine (Interleukin-6, 10 and 12) Levels at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Pico gram/milliliter (pg/mL)
Change From Baseline in Hormone-Like Cytokine (Interleukin-6, 10 and 12) Levels at Week 12
Pico gram/milliliter (pg/mL)Rebif Morning AdministrationRebif Evening Administration
Interleukin-6: Change at Week 12-0.5173 (-1.7940 to 0.7593)-0.6970 (-2.0624 to 0.6683)
Interleukin-10: Change at Week 12-0.05819 (-0.5453 to 0.4290)-0.6660 (-1.2999 to -0.03210)
Interleukin-12: Change at Week 12-0.3490 (-0.9115 to 0.2135)-0.4384 (-0.9973 to 0.1204)
SecondaryChange From Baseline in Total Sleep Time (TST) and Rapid Eye Movement (REM) Sleep Time at Week 12

Polysomnography (PSG) was performed for subjects who participated in the sub study. PSG is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.

Time frame:
Baseline and Week 12
Reported as:
Median · minutes
Change From Baseline in Total Sleep Time (TST) and Rapid Eye Movement (REM) Sleep Time at Week 12
minutesRebif Morning AdministrationRebif Evening Administration
Total Sleep Time: Change at Week 1210.0 (-73.0 to 117.0)33.0 (-227.0 to 165.0)
REM sleep: Change at Week 12-3.0 (-207.0 to 9.0)6.0 (-67.0 to 288.0)
SecondaryCorrelation Between Change From Baseline in Cytokines (Leptin, Resistin and Adiponectin) and Hormone-like Cytokine Levels (Interleukin-6, 10 and 12), and TST and REM Sleep Time at Week 12

Correlations between change from baseline at Week 12 in TST or REM sleep and the area under the curve (AUC) calculated using the trapezoidal method for cytokine levels (i.e., leptin, resistin, adiponectin, Interleukin (IL)-12, IL 10, and IL 6) were analyzed using Pearson's correlation coefficient. Polysomnography (PSG) was performed for subjects who participated in the sub study.

Time frame:
Baseline and Week 12
Reported as:
Number · Correlation Coefficient
Correlation Between Change From Baseline in Cytokines (Leptin, Resistin and Adiponectin) and Hormone-like Cytokine Levels (Interleukin-6, 10 and 12), and TST and REM Sleep Time at Week 12
Correlation CoefficientRebif Morning AdministrationRebif Evening Administration
AUC Leptin and TST: Week 120.108160.46984
AUC Resistin and TST: Week 12-0.56278-0.05056
AUC Adiponectin and TST: Week 120.174020.58181
AUC IL-12 and TST: Week 12-0.443280.24717
AUC IL-10 and TST: Week 121.00000NA
AUC IL-6 and TST: Week 120.18626-0.51662
AUC Leptin and REM: Week 120.997320.63155
AUC Resistin and REM: Week 120.22684-0.38234
AUC Adiponectin and REM: Week 120.98335-0.05732
AUC IL-12 and REM: Week 121.00000-0.76606
AUC IL-10 and REM: Week 12-1.00000NA
AUC IL-6 and REM: Week 120.06269-0.34860
SecondaryNumber of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation

An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug.

Time frame:
Baseline up to Week 12
Reported as:
Number · Subjects
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation
SubjectsRebif Morning AdministrationRebif Evening Administration
TEAEs8277
Serious TEAEs12
TEAEs Leading to Death00
TEAE leading to Discontinuation63

Adverse events

Collected over Baseline up to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rebif Morning Administration—1/104 (1%)77/104 (74%)
Rebif Evening Administration—2/96 (2.1%)70/96 (72.9%)
Most frequent serious events
Most frequent serious events
EventRebif Morning AdministrationRebif Evening Administration
Abortion SpontaneousPregnancy, puerperium and perinatal conditions0/1041/96
Deep Vein ThrombosisVascular disorders0/1041/96
Influenza Like IllnessGeneral disorders1/1040/96
Most frequent other events
Showing 10 of 16
Most frequent other events
EventRebif Morning AdministrationRebif Evening Administration
Influenza Like IllnessGeneral disorders52/10442/96
HeadacheNervous system disorders23/10416/96
PyrexiaGeneral disorders15/10411/96
Injection Site ErythemaGeneral disorders14/1048/96
NauseaGastrointestinal disorders10/1042/96
MyalgiaMusculoskeletal and connective tissue disorders10/1046/96
InsomniaPsychiatric disorders2/1049/96
FatigueGeneral disorders9/1042/96
Alanine Aminotransferase IncreasedInvestigations4/1047/96
ArthralgiaMusculoskeletal and connective tissue disorders5/1047/96

Baseline characteristics

The Intention to Treat Analysis Set (ITT) included all subjects enrolled into the study and assigned to the RebiSmart device.

Age, Customized
Age, Customized(subjects)Rebif Morning AdministrationRebif Evening AdministrationTotal
<18 years000
>=18 years to 64 years10496200
>64 years000
Sex: Female, Male
Sex: Female, Male(Participants)Rebif Morning AdministrationRebif Evening AdministrationTotal
Female7662138
Male283462
08

Study locations

1 site
  • Please contact the Merck KGaA Communication Center
    Darmstadt, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Apr 2016, 22 months.

Results were first posted in Sep 2018, 2 years 4 months after primary completion.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2014
First posted
Feb 17, 2014
StartActual
May 31, 2014
Primary completionActual
Apr 30, 2016
CompletionActual
Apr 30, 2016
Results first posted
Sep 20, 2018
Last update
Sep 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02064816
Responsible party
Sponsor
First posted
Feb 17, 2014
Start date
May 31, 2014
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016
Results posted
Sep 20, 2018
Last update
Sep 20, 2018

Study contacts

Medical Responsible
study director · Merck Serono S.P.A., Italy
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion